Plain English Summary
Background and study aims
This study will recruit 50 women with metastatic ovarian carcinoma (ovarian cancer that has spread) undergoing a tumour reduction operation. Colloid and crystalloid solutions are given into a patient’s vein (intravenously) during surgery to maintain blood volume. The aim of this study is to find out whether a colloid solution is better than a crystalloid solution for volume replacement (i.e. a lower amount of solution is needed).
Who can participate?
Women aged 18 or over with metastatic ovarian carcinoma undergoing a tumour reduction operation at the University Hospital, Campus Virchow-Klinikum of the Charité - University Medicine Berlin
What does the study involve?
Participants are randomly allocated to receive either a colloid or crystalloid solution intravenously during their surgery. The amount of fluid used is measured, along with other factors such as length of intensive care and hospital stay, complications, pain and quality of life.
What are the possible benefits and risks of participating?
There are no additional treatments or tests for the participants, and the study drugs are common medicines used in everyday hospital routine. The risk to participants is low and there is a low risk of side effects to the study drugs.
Where is the study run from?
Charité - University Medicine Berlin (Germany)
When is the study starting and how long is it expected to run for?
May 2009 to June 2011
Who is funding the study?
Charité - University Medicine Berlin (Germany)
Who is the main contact?
Prof. Claudia Spies
Trial website
Additional identifiers
EudraCT number
ClinicalTrials.gov number
Protocol/serial number
EK 12 581/08
Study information
Scientific title
Balanced crystalloids versus balanced colloids within a goal-directed haemodynamic protocol in patients undergoing gynaecological tumour resection: a prospective, randomised, controlled, double-blinded, two-armed single-centre trial
Acronym
BalaCriCo
Study hypothesis
A balanced colloid solution is superior to a balanced crystalloid solution for volume replacement in regard of lower amounts of intra-operatively administered intravenous solutions.
Ethics approval
Ethics Committee of the Landesamt für Gesundheit und Soziales Berlin (LaGeSo), Germany, 19/12/2008, ref: EK 12 581/08
Study design
Prospective randomised controlled double-blinded two-armed single-centre phase IV trial
Primary study design
Interventional
Secondary study design
Randomised controlled trial
Trial setting
Hospitals
Trial type
Treatment
Patient information sheet
Not available in web format, please use the contact details to request a patient information sheet
Condition
Gynaecological tumour resection
Intervention
During gynaecological tumour resection:
1. Intra-operative oesophageal Doppler guided fluid management with a balanced colloid solution
2. Intra-operative oesophageal Doppler guided fluid management with a balanced cristalloid solution
The dosage will be guided by the stroke volume and the corrected flow time of the heart measured by the oesophageal Doppler. The duration of the study protocol identical to the administration of the study medication is from the beginning of the operation up to the end of the operation. Total intravenous Dose per day is 50 ml/kg BW/d for Volulyte and 50 ml/kg BW per day for Jonosteril. Follow up will be 3 months after drug application for all arms.
Intervention type
Procedure/Surgery
Phase
Phase IV
Drug names
Primary outcome measures
Differences of intra-operatively administered amount of intravenous fluids (balanced colloid versus balanced crystalloid solutions) within a goal-directed haemodynamic management
Secondary outcome measures
1. Doses and duration of therapy with catecholamines measured intra-operatively and post-operatively during intensive care unit (ICU) stay
2. Time and number of hypotensive episodes measured intra-operatively and post-operatively during ICU stay
3. The quantity of intravenous fluid admininstered to the patient during the first 18 hours after surgery
4. The quantity of fluids per day lost by drainage during the first three days after surgery
5. Time that discharge criteria were met (measured by Post-Anaesthetic Discharge Scoring System [PADSS])
6. Length of intensive care stay and length of hospital stay (LOS)
7. The rate of post-operative organ dysfuntions and complications (cardiac, pulmonal, renal, gastrointestinal)
8. The rate of post-operative delirium and the post-operative incidence of post-operative, cognitive dysfunction
9. Weight change until the fifth post-operative day
10. Peri-operative incidence of infections (according to the Centers for Disease Control and Prevention [CDC] and American Thoracic Society [ATS] criteria)
11. Patient, surgeon and anaesthetic satisfaction
12. Pain of the patient
13. Quality of life measured before the operation, at the day of hospital discharge and three months after surgery
14. Laboratory tests: peri-operative endothelial and immunological alterations
The secondary outcome measures were determined if above not specified within the study up to the 10th post-operative day.
Overall trial start date
01/05/2009
Overall trial end date
30/06/2011
Reason abandoned
Eligibility
Participant inclusion criteria
1. Female patients aged 18 and over
2. Patients with metastatic ovarian carcinoma undergoing a tumour reduction operation at the University Hospital, Campus Virchow-Klinikum of the Charité - University Medicine Berlin
3. Offered patient information and written informed consent
4. No participation in another clinical trial during the trial until the 10th post-operative day
Participant type
Patient
Age group
Adult
Gender
Female
Target number of participants
50
Participant exclusion criteria
1. Aged less than 18 years
2. Pregnancy or lactation
3. Lacking willingness to save and hand out pseudonymised data within the clinical study
4. Accommodation in an institution due to an official or judicial order
5. Advanced disease of the oesophagus of nasopharyngeal cavity
6. Operations in the area of the oesophagus or nasopharynx within the last two months
7. Liver disease (Child B or C cirrhosis, end-stage liver disease [MELD] score greater than 10)
8. Conditions after acute or chronic pancreatitis
9. History of bleeding tendency, e.g. Von Willebrands disease
10. Neurological or psychiatric disease
11. Unclear history of alcohol related disorder
12. Chronic heart failure class IV according to the New York Heart Association (NYHA)
13. American Society of Anaesthesiologists (ASA) classification greater than III
14. Renal insufficiency (serum creatinine greater than 2.0 mg/dl or greater than 150 µmol/l or dependency of haemodialysis)
15. Existence of a pulmonary oedema in the pre-operative chest x-ray
16. Allergy to hydroxyethyl starch or other ingredients of the intravenous solutions
17. History of intracranial haemorrhage within one year before participation in the study
18. Hyperkalaemia greater than 5.8 mmol/l and hypernatriaemia greater than 155 mmol/l
19. Pre-operative ileus symptomatology
20. Known history of hypermagnesaemia
21. Known history of metabolic alkalosis
22. Derailed diabetes mellitus (glucose greater than 300 mg/dl) before inclusion
Recruitment start date
01/05/2009
Recruitment end date
30/06/2011
Locations
Countries of recruitment
Germany
Trial participating centre
Charité - University Medicine Berlin (Charité - Universitätsmedizin Berlin)
Berlin
13353
Germany
Sponsor information
Organisation
Charité - University Medicine Berlin (Charité - Universitätsmedizin Berlin) (Germany)
Sponsor details
Charitéplatz 1
Berlin
10117
Germany
-
c.krukenkamp@charite.de
Sponsor type
University/education
Website
Funders
Funder type
University/education
Funder name
Charité Universitätsmedizin Berlin
Alternative name(s)
Funding Body Type
private sector organisation
Funding Body Subtype
corporate
Location
Germany
Results and Publications
Publication and dissemination plan
Not provided at time of registration
Intention to publish date
Participant level data
Not provided at time of registration
Results - basic reporting
Publication summary
2012 results in: http://www.ncbi.nlm.nih.gov/pubmed/23112214
2017 substudy results in: http://www.ncbi.nlm.nih.gov/pubmed/28700473
Publication citations
-
Results
Feldheiser A, Pavlova V, Bonomo T, Jones A, Fotopoulou C, Sehouli J, Wernecke KD, Spies C, Balanced crystalloid compared with balanced colloid solution using a goal-directed haemodynamic algorithm., Br J Anaesth, 2013, 110, 2, 231-240, doi: 10.1093/bja/aes377.